Skip to main content
Top
Gepubliceerd in: Mednet 8/2014

01-12-2014 | CME Oncologie

Diagnostiek en behandeling van pijn bij kanker

Auteur: Dr. A. De Graeff

Gepubliceerd in: Mednet | Uitgave 8/2014

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Pijn bij patiënten met kanker is meestal chronisch van karakter. Tegen de achtergrond van deze chronische pijn kan een plotselinge toename van pijn optreden, de zogenoemde doorbraakpijn. Deze CME Oncologie gaat over Doorbraakpijn.
Literatuur
1.
go back to reference Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331-8.PubMedCrossRef Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331-8.PubMedCrossRef
2.
go back to reference Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence- based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-68.PubMedCrossRef Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence- based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-68.PubMedCrossRef
3.
go back to reference Wengström Y, Geerling J, Rustoen T. European Oncology Nursing Society breakthrough cancer pain guidelines. Eur J Oncol Nurs. 2013 Dec 23. [Epub ahead of print] Wengström Y, Geerling J, Rustoen T. European Oncology Nursing Society breakthrough cancer pain guidelines. Eur J Oncol Nurs. 2013 Dec 23. [Epub ahead of print]
4.
go back to reference Davies A, Zeppetella G, Andersen S, et al. Multicentre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;13:756-63.CrossRef Davies A, Zeppetella G, Andersen S, et al. Multicentre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;13:756-63.CrossRef
5.
go back to reference Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013;46:619-28.PubMedCrossRef Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013;46:619-28.PubMedCrossRef
6.
go back to reference Deandrea S, Corti O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014;47:57-76.PubMedCrossRef Deandrea S, Corti O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014;47:57-76.PubMedCrossRef
7.
8.
go back to reference Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-34.PubMedCrossRef Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-34.PubMedCrossRef
9.
go back to reference Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87-92.PubMedCrossRef Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87-92.PubMedCrossRef
10.
go back to reference Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-83.PubMedCrossRef Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-83.PubMedCrossRef
11.
go back to reference Zeppetella G. Breakthrough pain in cancer patients. Clin Oncol (R Coll Radiol). 2011;23:393-8.CrossRef Zeppetella G. Breakthrough pain in cancer patients. Clin Oncol (R Coll Radiol). 2011;23:393-8.CrossRef
12.
go back to reference Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3:38-44.PubMedCrossRef Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3:38-44.PubMedCrossRef
13.
14.
go back to reference Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611-6.PubMedCrossRef Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611-6.PubMedCrossRef
15.
go back to reference Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release ((MSIR). Pain. 2001;91:1123-30.CrossRef Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release ((MSIR). Pain. 2001;91:1123-30.CrossRef
16.
go back to reference Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodicbreakthrough pain. Br J Cancer. 2007;96:1828-33.PubMedCentralPubMedCrossRef Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodicbreakthrough pain. Br J Cancer. 2007;96:1828-33.PubMedCentralPubMedCrossRef
17.
go back to reference Portenoy RK, Taylor D, Messina J, et al. A randomized, placebocontrolled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-11.PubMedCrossRef Portenoy RK, Taylor D, Messina J, et al. A randomized, placebocontrolled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-11.PubMedCrossRef
18.
go back to reference Slatkin NL, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioidtolerant patients with cancer-related pain. J Support Oncol. 2007;5:327-34.PubMed Slatkin NL, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioidtolerant patients with cancer-related pain. J Support Oncol. 2007;5:327-34.PubMed
19.
go back to reference Kosugi T, Hamada S, Takigawa C, et al. A randomized, double-blind, placebo- controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. J Pain Symptom Manage. 2013 Oct 5. [Epub ahead of print] Kosugi T, Hamada S, Takigawa C, et al. A randomized, double-blind, placebo- controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. J Pain Symptom Manage. 2013 Oct 5. [Epub ahead of print]
20.
go back to reference Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308-14.PubMedCentralPubMedCrossRef Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308-14.PubMedCentralPubMedCrossRef
21.
go back to reference Rauck RL, Tark M, Reues E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrated tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877-85.PubMedCrossRef Rauck RL, Tark M, Reues E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrated tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877-85.PubMedCrossRef
22.
go back to reference Lennernäs B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effctive treatment for breakthrough pain: results from a randomized phase II study. Palliat Med. 2010;24:286-93.PubMedCrossRef Lennernäs B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effctive treatment for breakthrough pain: results from a randomized phase II study. Palliat Med. 2010;24:286-93.PubMedCrossRef
Metagegevens
Titel
Diagnostiek en behandeling van pijn bij kanker
Auteur
Dr. A. De Graeff
Publicatiedatum
01-12-2014
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Mednet / Uitgave 8/2014
Print ISSN: 1568-7716
Elektronisch ISSN: 1876-5963
DOI
https://doi.org/10.1007/s12462-014-0242-9

Andere artikelen Uitgave 8/2014

Mednet 8/2014 Naar de uitgave